Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
ScTIL
Suzhou, Jiangsu, China
- Ownership
- Private
- Development stage
- Other
01
Overview
ScTIL is a clinical-stage biotechnology company based in China that specializes in the development of next-generation Tumor-Infiltrating Lymphocyte (TIL) therapies for solid tumors. The company utilizes a proprietary single-cell analysis and screening platform to identify and expand the most potent tumor-reactive T cells from a patient's own tumor tissue. By optimizing the selection process, ScTIL aims to overcome the limitations of traditional TIL therapies, such as low cell purity and inconsistent efficacy. Their lead programs are currently being evaluated in clinical trials for various advanced solid malignancies, including lung and gynecological cancers.
- Therapeutic areas
- Oncology
- Modalities
- Cell therapyTIL cell therapy
- Industry
- Biotech
Beyond the preview
Go deeper on ScTIL.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ScTIL.